Phase II study of docetaxel, cisplatin and 5-fluorouracil (DCF) for metastatic esophageal cancer (OGSG 0403)

Anticancer Research

Volumn 32, Issue 4, 2012, Pages 1403-1408

  Tamura, Shigeyuki ^a   Imano, Motohiro ^b   Takiuchi, Hiroya ^c   Kobayashi, Kenji ^d   Imamoto, Haruhiko ^b   Miki, Hirofumi ^a   Goto, Yoshihiro ^c   Aoki, Taro ^d   Peng, Ying Feng ^b   Tsujinaka, Toshimasa ^e   Furukawa, Hiroshi ^f  

^a KANSAI ROSAI HOSPITAL   (Japan)

^b KINKI UNIVERSITY   (Japan)

^c OSAKA MEDICAL COLLEGE   (Japan)

^d Kinki Central Hospital of Mutual Association of Public School Teachers   (Japan)

^e OSAKA MEDICAL COLLEGE   (Japan)

^f SAKAI MUNICIPAL HOSPITAL   (Japan)

Author keywords

Cisplatin; Combination chemotherapy; Docetaxel; Fluorouracil; Metastatic esophageal cancer

Indexed keywords

CISPLATIN; DEXAMETHASONE; DOCETAXEL; FLUOROURACIL;

ADULT; AGED; ALOPECIA; ANOREXIA; ARTICLE; CANCER CHEMOTHERAPY; CANCER PATIENT; CLINICAL ARTICLE; CONFIDENCE INTERVAL; CONTINUOUS INFUSION; DIARRHEA; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG TOLERABILITY; ESOPHAGEAL SQUAMOUS CELL CARCINOMA; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; HUMAN; LEUKOPENIA; MALE; METASTASIS; MULTICENTER STUDY; NAUSEA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; STOMATITIS; THROMBOCYTOPENIA; TREATMENT RESPONSE; VOMITING;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CISPLATIN; ESOPHAGEAL NEOPLASMS; FEMALE; FLUOROURACIL; HUMANS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; TAXOIDS;

EID: 84859966845     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. De Besi P, Sileni VC, Salvagno L, Tremolada C, Cartei G, Fosser V, Paccagnella A, Peracchia A and Fiorentino M: Phase II study of cisplatin, 5-FU, and allopurinol in advanced esophageal cancer. Cancer Treat Rep 70: 909-910 1986. (Pubitemid 16058560)
2. Kies MS, Rosen ST, Tsang TK, Shetty R, Schneider PA, Wallenmark CB and Shields TW: Cisplatin and 5-fluorouracil in the primary management of squamous esophageal cancer. Cancer 60: 215-216, 1987.
3. Bleiberg H, Conroy T, Paillot B, Lacave AJ, Blijham G, Jacob JH, Bedenne L, Namer M, De Besi P, Gay F, Collette L and Sahmoud T: Randomised phase II study of cisplatin and 5-fluorouracil (5-FU) versus cisplatin alone in advanced squamous cell oesophageal cancer. Eur J Cancer 33: 1216-1220, 1997. (Pubitemid 27359638)
4. Warner E, Jensen JL, Cripps C, Khoo KE, Goel R, Kerr IA, Bjarnason GA, Fields AL and Hrincu A: Outpatient 5-fluorouracil, folinic acid and cisplatin in patients with advanced esophageal carcinoma. Acta Oncol 38: 255-259, 1999. (Pubitemid 29179782)
5. Iizuka T, Kakegawa T, Ide H, Ando N, Watanabe H, Tanaka O, Takagi I, Isono K, Ishida K, Arimori M, Endo M and Fukushima: Phase II evaluation of cisplatin and 5-fluorouracil in advanced squamous cell carcinoma of the esophagus: a Japanese Esophageal Oncology Group trial. Jpn J Clin Oncol 22: 172-176, 1992.
6. Hayashi K, Ando N, Watanabe H, Ide H, Nagai K, Aoyama N, Takiyama W, Ishida K, Isono K, Makuuchi H, Imamura M, Shinoda M, Ikeuchi S, Kabuto T, Yamana H and Fukuda H: Phase II evaluation of protracted infusion of cisplatin and 5-fluorouracil in advanced squamous cell carcinoma of the esophagus: a Japan Esophageal Oncology Group (JEOG) Trial (JCOG9407). Jpn J Clin Oncol 31: 419-423, 2001. (Pubitemid 33039748)
7. Vermorken JB, Remenar E, van Herpen C, Gorlia T, Mesia R, Degardin M, Stewart JS, Jelic S, Betka J, Preiss JH, van den Weyngaert D, Awada A, Cupissol D, Kienzer HR, Rey A, Desaunois I, Bernier J and Lefebvre JL; EORTC 24971/TAX 323 Study Group: Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer. N Engl J Med 357: 1695-1704, 2007.
8. Posner MR, Hershock DM, Blajman CR, Mickiewicz E, Winquist E, Gorbounova V, Tjulandin S, Shin DM, Cullen K, Ervin TJ, Murphy BA, Raez LE, Cohen RB, Spaulding M, Tishler RB, Roth B, Viroglio Rdel C, Venkatesan V, Romanov I, Agarwala S, Harter KW, Dugan M, Cmelak A, Markoe AM, Read PW, Steinbrenner L, Colevas AD, Norris CM Jr. and Haddad RI; TAX 324 Study Group: Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer. N Engl J Med 357: 1705-1715, 2007. (Pubitemid 350005152)
9. Ajani JA, Fodor MB, Tjulandin SA, Moiseyenko VM, Chao Y, Cabrai Filho S, Majlis A, Assadourian S and Van Cutsem E: Phase II multi-institutional randomized trial of docetaxel plus cisplatin with or without fluorouracil in patients with untreated, advanced gastric, or gastroesophageal adenocarcinoma. J Clin Oncol 23: 5660-5667, 2005.
10. Van Cutsem E, Moiseyenko VM, Tjulandin S, Majlis A, Constenla M, Boni C, Rodrigues A, Fodor M, Chao Y, Voznyi E, Risse ML and Ajani JA; V325 Study Group: Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group. J Clin Oncol 24: 4991-4997, 2006. (Pubitemid 46631401)
11. Tanaka T, Fujita H, Sueyoshi S, Tanaka Y, Sasahara H, Mori N, Nagano T, Yamana H and Shirouzu K: Second-line combination chemotherapy with docetaxel for cisplatin-pretreated refractory metastatic esophageal cancer: a preliminary report of initial experience. Chemotherapy 53: 449-453, 2007. (Pubitemid 350085262)
12. Japan Esophageal Society: Japanese Classification of Esophageal Cancer, tenth edition: part 1. Esophagus 6: 1-25, 2009.
13. Greene FL, Page DL, Fleming ID, Fritz A, Balch CM, Haller DG, Morrow M (eds.). AJCC Cancer Staging Manual, 6th edition. New York: Springer, 2002.
14. Therasse P, Arbuck SG, Eisenhauer E, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC and Gwyther SG: New Guidelines to Evaluate the Response to Treatment in Solid Tumors. J Natl Cancer inst 92: 205-216, 2000. (Pubitemid 30099779)
15. Trotti A, Byhardt R, Stetz J, Gwde C, Corn B, Fu K, Gunderson L, McCormick B, Morrisintegral M, Rich T, Shipley W and Curran W: Common toxicity criteria: version 2.0. an improved reference for grading the acute effects of cancer treatment: impact on radiotherapy. Int J Radiat Oncol Biol Phys 47: 13-47, 2000. (Pubitemid 30179675)
16. Takahashi H, Arimura Y, Yamashita K, Okahara S, Tanuma T, Kodaira J Hokari K, Tsukagoshi H, Shinomura Y and Hosokawa M: Phase I/II study of docetaxel/cisplatin/fluorouracil combination chemotherapy against metastatic esophageal squamous cell carcinoma. J Thorac Oncol 5: 122-128, 2010.
17. Overman MJ, Kazmi SM, Jhamb J, Lin E, Yao JC, Abbruzzese JL, Ho L, Ajani J and Phan A: Weekly docetaxel, cisplatin, and 5-fluorouracil as initial therapy for patients with advanced gastric and esophageal cancer. Cancer 116: 1446-1453, 2010.
18. Tebbutt NC, Cummins MM, Sourjina T, Strickland A, Van Hazel G, Ganju V, Gibbs D, Stockier M, Gebski V and Zalcberg J; Australasian Gastro-Intestinal Trials Group: Randomised, non-comparative phase II study of weekly docetaxel with cisplatin and 5-fluorouracil or with capecitabine in oesophagogastric cancer: the AGITG ATTAX trial. Br J Cancer 102: 475-481, 2010.
19. Osaka Y, Shinohara M, Hoshino S, Ogata T, Takagi Y, Tsuchida A and Aoki T: Phase II study of combined chemotherapy with docetaxel, CDDP and 5-FU for highly advanced esophageal cancer. Anticancer Res 31: 633-638, 2011.
20. Yamasaki M, Miyata H, Tanaka K, Shiraishi O, Motoori M, Peng YF, Yasuda T, Yano M, Shiozaki H, Mori M and Doki Y: Multicenter phase I/II study of docetaxel, cisplatin and fluorouracil combination chemotherapy in patients with advanced or recurrent squamous cell carcinoma of the esophagus. Oncology 80: 307-313, 2011.
21. Park SR, Chun JH, Kim YW, Ue JH, Choi IJ, Kim CG, Lee JS, Bae JM and Kim HK: Phase II study of low-dose docetaxel/fluorouracil/ cisplatin in metastatic gastric carcinoma. Am J Clin Oncol 28: 433-438, 2005. (Pubitemid 41439735)
22. Watanabe M, Nagai Y, Kinoshita K, Saito S, Kurashige J, Karashima R, Hirashima K, Sato N, Imamura Y, Hiyoshi Y, Baba Y, Iwagami S, Miyamoto Y, Iwatsuki M, Hayashi N and Baba H: Induction chemotherapy with docetaxel/cisplatin/5-fluorouracil for patients with node-positive esophageal cancer. Digestion 83: 146-152, 2011.
23. Miyata H, Yano M, Yasuda T, Hamano R, Yamasaki M, Hou E, Motoori M, Shiraishi O, Tanaka K, Mori M and Doki Y: Randomized study of clinical effect of enteral nutrition support during neoadjuvant chemotherapy on chemotherapy-related toxicity in patients with esophageal cancer. Clin Nutr 2011 [Epub ahead of print].